German pharmaceutical company Boehringer Ingelheim has reported that its experimental obesity drug, survodutide, significantly reduced visceral abdominal fat and liver fat while largely preserving lean body mass in a late-stage clinical study. The data strengthens the company’s argument that the drug offers meaningful health benefits beyond overall weight loss percentage a distinction that analysts have identified as critical for commercial success in an increasingly competitive obesity drug market.
Survodutide, an injectable drug licensed from Denmark’s Zealand Pharma in 2011, works by mimicking two proteins GLP-1 and glucagon to produce a sense of fullness. Its weight-loss trial results, announced in April, showed that patients lost an average of 16.6% of their body weight over 76 weeks. The newly released analysis, drawn from patients who had MRI measurements taken at both the start and the end of the 76-week trial, showed that survodutide reduced harmful abdominal fat by up to 34% and liver fat by up to 63.1% from baseline. Notably, lean mass accounted for no more than 10.8% of the total change in body composition at the highest dose of 6 milligrams, indicating that the weight loss was driven predominantly by fat reduction rather than muscle loss.
Analysts had previously noted that survodutide’s overall weight-loss numbers were broadly comparable to existing GLP-1 injections from Novo Nordisk and Eli Lilly, and fell below some newer rivals still in development. They stressed that Boehringer would need to differentiate the drug on other clinical dimensions. The detailed data on survodutide fat loss distribution and lean mass preservation are now central to that differentiation, alongside the drug’s tolerability profile and patient retention rates. “We believe survodutide will become an important new option at the intersection of obesity and liver disease, two conditions that are deeply connected but rarely addressed together,” said Shashank Deshpande, who leads Boehringer Ingelheim’s human medicines business. Under the licensing arrangement, Zealand Pharma holds the right to receive royalty payments on global revenue generated by the drug.
In a separate late-stage study involving overweight or obese patients with a fatty liver disease known as MASLD, survodutide met both of its primary endpoints. After 48 weeks of treatment, up to 84.2% of patients receiving the drug achieved a liver fat reduction of at least 30%, compared to 24.3% among those on placebo. Patients on survodutide also lost up to 12.2% of their body weight, versus just 1% for the placebo group. In 61% of patients, the drug achieved liver fat normalization defined as a liver fat content below 5% compared with only 5.7% on placebo. Survodutide is additionally being evaluated in further late-stage studies involving patients with fatty liver disease and fibrosis. U.S. biotech Altimmune is also developing a compound targeting both GLP-1 and glucagon, placing it in a similar therapeutic space as survodutide.
